ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 33

Stimulation of the Adenosine a2A receptor (A2AR) Regulates the Expression of Netrin1 and Their Receptors (Unc5b, DCC) and Inhibits Osteoclast Differentiation and Inflammatory Bone Destruction

Aranzazu Mediero1, Bhama Ramkhelawon2, Miguel Perez-Aso3, Kathryn Moore2 and Bruce N. Cronstein4, 1Medicine, Division of Translational Medicine, NYU School of Medicine, New York, NY, 2Leon H. Charney Division of Cardiology, Department of Medicine,, NYU School of Medicine, New York, NY, 3545 1st Ave., New York University, New York City, NY, 4NYU School of Medicine, Division of Rheumatology, New York, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Adenosine receptors, Inflammation, osteoclastogenesis and osteoclasts

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint: Osteoclasts, Osteoblasts and Bone Remodeling

Session Type: Abstract Submissions (ACR)

Background/Purpose A variety of molecules mediate communication between osteoclasts and osteoblasts during bone remodeling. Netrin1 is a member of the family of axonal guidance proteins, that regulates inflammation and macrophage function.  Because osteoclasts are derived from myeloid precursors we asked whether osteoclasts expressed Netrin-1 and whether A2AR activation, which diminishes osteoclast differentiation, might regulate Netrin-1 expression and inflammatory osteolysis.

Methods 1cm midline sagittal incision was made over the calvaria in C57Bl/6 mice age 6-8 weeks. Mice received no particles (Control) or 3mg of UHMWPE with 20µl of saline 0.9% or CGS21680 (A2AR agonist, 1µM, n=4 each) at the surgical site every day up to 14 days. After sacrifice, calvaria were prepared for immunostaining for Netrin1/Unc5b/DCC. Protein and mRNA expression were studied by RT-PCR and WB in mouse and human primary bone marrow-derived OC and OB in the presence/absence of CGS21680 and ZM241385 (A2AR antagonist) 1µM each.

Results UHMWPE increased expression of Netrin1 and Unc5b, but not DCC, in periosteal inflammatory infiltrates which was reversed by the A2AR agonist CGS21680. RANKL induced 25±4 and 3±0.5 fold change, respectively, in Netrin1 and Unc5b mRNA during osteoclast differentiation, changes that were completely blocked by CGS21680 (1.17±0.1, p<0.001, n=4). In contrast, DCC mRNA expression did not significantly change during osteoclast differentiation and DCC expression was unaffected by CGS21680 (1.16±0.2 fold increase vs 1.9±0.2 for RANKL, p=ns, n=4). There was no change in Netrin1 or Unc5b expression during OB differentiation. Similar changes were observed in protein expression and secretion.

 Conclusion UHMWPE-induced osteolysis is regulated by Netrin1 activation. Adenosine A2AR stimulation normalizes Netrin1expression and inhibits bony destruction at sites of UHMWPE-induced osteolysis. These results suggest that targeting Netrin1 directly or via stimulation of adenosine A2AR may be a novel approach to preventing osteolysis and joint prosthesis loosening.


Disclosure:

A. Mediero,
None;

B. Ramkhelawon,
None;

M. Perez-Aso,
None;

K. Moore,
None;

B. N. Cronstein,

Canfite Pharma,

1,

AstraZeneca,

2,

Cellgene,

2,

Gilead,

2,

NIH,

2,

NYU School of Medicine,

3,

Bristol-Myers Squibb,

5,

Pfizer Inc,

5,

Eli Lilly and Company,

5,

Rheumatology Reseach Foundation,

6,

ACR,

6,

Arthritis Foundation,

6.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/stimulation-of-the-adenosine-a2a-receptor-a2ar-regulates-the-expression-of-netrin1-and-their-receptors-unc5b-dcc-and-inhibits-osteoclast-differentiation-and-inflammatory-bone-destruction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology